Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06720987 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
A Phase 1 study of Solid Tumor Malignancies and CRC, Colorectal Cancer, sponsored by Kumquat Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
- 9
- Study locations
NCT06720987: Recruiting Phase 1 study of Solid Tumor Malignancies and CRC, Colorectal Cancer, sponsored by Kumquat Biosciences.
NCT06720987 is a Phase 1 study of Solid Tumor Malignancies and CRC, Colorectal Cancer that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 128 participants, below the 184-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (30% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06720987, a Phase 1 study of Solid Tumor Malignancies and CRC, Colorectal Cancer, is actively recruiting participants, sponsored by Kumquat Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself or in combination with cetuximab? * Does KQB365 alone or in combination with cetuximab decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone or in combination with cetuximab * Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.
Primary Outcome
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 30 days after last dose of study treatment.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG KQB365
Study Locations (9)
Arizona
- Mayo Clinic, Phoenix - Phoenix
Colorado
- Sarah Cannon Cancer Institute at HealthONE - Denver
Florida
- Mayo Clinic, Jacksonville - Jacksonville
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
Minnesota
- Mayo Clinic, Rochester - Rochester
Ohio
- Cleveland Clinic, Taussig Cancer Institute - Cleveland
Texas
- NEXT Oncology - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 1 |
What NCT06720987 shows while recruiting
NCT06720987 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 184-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (30% lower).
The record links to 4 conditions, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT06720987 lists 9 locations in 9 states (Arizona, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT06720987 about?
NCT06720987 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself or in combination with cetuximab? * Does KQB365 alone or i...
What is the current status of trial NCT06720987?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2025-02-04. Estimated completion is 2030-06-30.
What conditions does trial NCT06720987 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies, CRC, Colorectal Cancer, KRAS G12C Mutation, KRAS G12S Mutation.
What interventions are being tested in trial NCT06720987?
The interventions under investigation include: Cetuximab (DRUG), KQB365 (DRUG).
Who is sponsoring clinical trial NCT06720987?
This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06720987 being conducted?
This trial has 9 study locations across Arizona, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06720987's enrollment target sits among peer trials
128 7th of 11 higher than 5 of 11 other Solid Tumor Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI